Summary:

One of the largest overseas acquisitions by an Indian pharmaceutical business, Sun Pharmaceutical Industries Ltd., announced the purchase of US-based Organon & Co. in an all-cash deal valued ₹10.86 lakh crore (US$11.75 billion). The acquisition, which has been approved by both boards, is anticipated to completion by early 2027 and gives ₹1,294.16 (US$14) per share. Through the acquisition, Sun Pharma now has more than 70 Organon products in women's health, general medications, and biosimilars in more than 140 countries. It will improve Sun's standing in niche markets like biologics, oncology, and dermatology. Internal accruals and bank funding will be used to finance the transaction, increasing size, diversification, and long-term profitability globally.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.